LEXINGTON, Mass.--(BUSINESS WIRE)--EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX) a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform today announced that its Form 10-K filed with the Securities and Exchange Commission on March 13, 2009 included a going concern qualification from its independent registered accounting firm, Ernst & Young LLP.
